Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.655 USD | +3.18% | +3.73% | +18.05% |
04:55pm | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
05-08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.05% | 444M | |
+24.39% | 46.71B | |
+48.83% | 41.8B | |
-1.08% | 41.52B | |
-3.42% | 29.55B | |
+10.27% | 25.78B | |
-21.33% | 19.26B | |
+0.83% | 12.14B | |
-3.27% | 12.08B | |
+27.05% | 11.98B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- JPMorgan Upgrades C4 Therapeutics to Neutral From Underweight, Price Target is $6